Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Merestinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 11/20 | 1.00 |
| ▸ | AXL | P30530 | 17/20 | 1.00 |
| ▸ | MERTK | Q12866 | 4/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | MST1R | Q04912 | 1/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 1/20 | 1.00 |
| ▸ | CAMK4 | Q16566 | 1/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 1/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Merestinib SCHEMBL29493094 | 1.00 | AXL (1.00) | AXLMETMERTKPLK4NTRK1 | |
| Merestinib SCHEMBL29726013 | 0.99 | AXL (0.99) | AXLMETMERTKPLK4NTRK1 | |
| Merestinib SCHEMBL680728 | 0.99 | AXL (0.99) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL22996143 | 0.96 | AXL (0.92) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL679128 | 0.95 | MET (0.91) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL18506507 | 0.94 | AXL (0.89) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629471 | 0.94 | AXL (0.88) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629478 | 0.93 | AXL (0.87) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629434 | 0.93 | AXL (0.87) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629501 | 0.92 | AXL (0.86) | AXLMETMERTKPLK4NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 980 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605370-B2 | Agents and compositions for the treatment of glioblastoma | UNIVERSITY OF CINCINNATI (US) | 2026-04-21 | — | — | US | claimed |
| US-20260069610-A1 | INHIBITION OF EFFEROCYTOSIS AS A TREATMENT TO PREVENT BONE LOSS AND INCREASE BONE DENSITY AND STRENGTH | UNIVERSITY OF ROCHESTER (US) | 2026-03-12 | — | — | US | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| WO-2025238172-A1 | COMBINATIONS OF BRAF AND ALK/TRK INHIBITORS FOR COLORECTAL CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | claimed |
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-10-23 | — | — | US | claimed |
| EP-4633630-A1 | TREATMENT OF CANCER RESISTANT TO EGFR TKI USING C-MET INHIBITOR | Apollomics Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| EP-3957631-B1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2025-09-10 | — | — | EP | claimed |
| EP-4605397-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | Nuvalent, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| EP-4604920-A1 | LYOPHILIZED FORMULATIONS OF CD73 COMPOUNDS | Arcus Biosciences, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| WO-2017027544-A1 | COMBINATION THERAPY FOR CANCER | IMCLONE LLC (US) | 2017-02-16 | — | — | WO | claimed |
| US-9260531-B2 | Anti-c-met antibodies | ELI LILLY AND COMPANY (US) | 2016-02-16 | — | — | US | claimed |
| US-20150118238-A1 | Anti-c-Met Antibodies | ELI LILLY AND COMPANY | 2015-04-30 | — | — | US | claimed |
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | claimed |
| EP-2310382-B1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | claimed |
| JP-2011529054-A | — | — | 2011-12-01 | — | — | JP | claimed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | claimed |
| EP-2310382-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | Eli Lilly & Company (US) | 2011-04-20 | — | — | EP | claimed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | claimed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ROS1, MCL1, ALK | MET 112/4885AXL 1034/4885MERTK 1958/4885 |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | MET 124/4885AXL 497/4885MERTK 298/4885 |
| US-12605370-B2 | Agents and compositions for the treatment of glioblastoma | PIK3R2, PIK3R1, PIK3R3 | MET 98/4885AXL 696/4885MERTK 535/4885 |
| US-20150118238-A1 | Anti-c-Met Antibodies | MET, HGF, HGFAC | MET 1/4885AXL 501/4885MERTK 9/4885 |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | MET, MYCBP, MYC | MET 1/4885AXL 113/4885MERTK 10/4885 |
| US-20260069610-A1 | INHIBITION OF EFFEROCYTOSIS AS A TREATMENT TO PREVENT BONE LOSS AND INCREASE BONE DENSITY AND STRENGTH | SOST, BST2, CALCR | MET 1298/4885AXL 312/4885MERTK 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.